OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
Lili Mao, Bin Lian, Caili Li, et al.
JAMA Oncology (2023) Vol. 9, Iss. 8, pp. 1099-1099
Open Access | Times Cited: 17
Lili Mao, Bin Lian, Caili Li, et al.
JAMA Oncology (2023) Vol. 9, Iss. 8, pp. 1099-1099
Open Access | Times Cited: 17
Showing 17 citing articles:
Management of acral lentiginous melanoma: current updates and future directions
Michelle M. Dugan, Matthew Perez, Lilit Karapetyan, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 10
Michelle M. Dugan, Matthew Perez, Lilit Karapetyan, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 10
Programmed cell death in tumor immunity: mechanistic insights and clinical implications
Man Wang, Fei Yu, Yuan Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 9
Man Wang, Fei Yu, Yuan Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 9
Adjuvant treatment with anti‐PD ‐1 in acral melanoma: A nationwide study
Manja Bloem, Olivier J. van Not, Maureen J.B. Aarts, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 8, pp. 1455-1465
Open Access | Times Cited: 6
Manja Bloem, Olivier J. van Not, Maureen J.B. Aarts, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 8, pp. 1455-1465
Open Access | Times Cited: 6
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
Qingjian He, Junling Lin, Chaohua Mo, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Qingjian He, Junling Lin, Chaohua Mo, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Analysis of the correlation between the dose exposure intensity and apatinib in advanced gastric cancer: a retrospective cohort study
Xiao Ma, Lan Gao, Shunan Che, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Xiao Ma, Lan Gao, Shunan Che, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Progress in immunotherapy for brain metastatic melanoma
Shicheng Zheng, Zhongqiao Lin, Ruibo Zhang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Shicheng Zheng, Zhongqiao Lin, Ruibo Zhang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy
Hejing Bao, Jiani Zhang, Xi Luo, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Hejing Bao, Jiani Zhang, Xi Luo, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review
Yanling Zhang, Xifeng Zhang, Weikang Shao, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 4
Open Access
Yanling Zhang, Xifeng Zhang, Weikang Shao, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 4
Open Access
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Katrin Schaper‐Gerhardt, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (2024) Vol. 202, pp. 113984-113984
Open Access | Times Cited: 3
Katrin Schaper‐Gerhardt, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (2024) Vol. 202, pp. 113984-113984
Open Access | Times Cited: 3
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma
Paweł Sobczuk, Michał Cholewiński, Piotr Rutkowski
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 5, pp. 501-510
Closed Access | Times Cited: 2
Paweł Sobczuk, Michał Cholewiński, Piotr Rutkowski
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 5, pp. 501-510
Closed Access | Times Cited: 2
Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes
Adrienne B. Shannon, Jonathan S. Zager, Matthew Perez
Cancers (2024) Vol. 16, Iss. 13, pp. 2395-2395
Open Access | Times Cited: 1
Adrienne B. Shannon, Jonathan S. Zager, Matthew Perez
Cancers (2024) Vol. 16, Iss. 13, pp. 2395-2395
Open Access | Times Cited: 1
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial
Wenjuan Tian, Ren Yulan, Jing Lü, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Wenjuan Tian, Ren Yulan, Jing Lü, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
British Journal of Dermatology (2024)
Closed Access | Times Cited: 1
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
British Journal of Dermatology (2024)
Closed Access | Times Cited: 1
Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review
Yinfang Gu, Lilan Yi, Xiaofang Zou, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Yinfang Gu, Lilan Yi, Xiaofang Zou, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Combined Pd-1 and Ctla-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
(2024)
Closed Access
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
(2024)
Closed Access
A Call for Innovative Translational and Clinical Research to Address China’s Unique Cancer Landscape
Chaoqi Zhang, Peng Wu, Dongyu Li, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2028-2032
Closed Access
Chaoqi Zhang, Peng Wu, Dongyu Li, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2028-2032
Closed Access
Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment
Li Zhou, Min Cao, Hai‐Bin Zhu, et al.
The Oncologist (2024)
Open Access
Li Zhou, Min Cao, Hai‐Bin Zhu, et al.
The Oncologist (2024)
Open Access
